111In-ETN029

111In-ETN029 is a **radiopharmaceutical diagnostic imaging agent** under development by Novartis, primarily intended to visualize and characterize solid tumors expressing DLL3. It consists of ETN029, a targeting ligand, labelled with the radioisotope **indium-111**. Upon administration, 111In-ETN029 binds to DLL3-expressing tumor cells, allowing for imaging via gamma cameras due to the gamma emission of indium-111. It is being studied in early clinical trials as a companion imaging agent to 225Ac-ETN029, which is designed for radioligand therapy. The primary indication is for use in patients with **advanced DLL3-positive cancers**, including small cell lung carcinoma, large cell neuroendocrine carcinoma of the lung, neuroendocrine prostate cancer, and gastroenteropancreatic neuroendocrine carcinoma.

Other names

indium-111 ETN029indium111 ETN029indium 111 ETN029